Cui Xiangmin
SEC-identified person · CIK 1487815 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Panacea Acquisition Corp PANA | Director | filed 2024 - 2026 |
| Beyondspring Inc. BYSI | Officer | filed 2025 - 2025 |
| Aardvark Therapeutics, Inc. AARD | Officer | filed 2025 - 2025 |
| Nivalis Therapeutics, Inc. NVLS | Director | filed 2019 - 2024 |
| CG Oncology, Inc. CGON | Officer | filed 2024 - 2024 |
| Cue Health Inc. HLTH | Director | filed 2021 - 2021 |
| Equillium, Inc. EQ | Officer | filed 2021 - 2021 |
| Armo Biosciences, Inc. ARMO | Director | filed 2018 - 2018 |
| China Biologic Products, Inc. CPBO | Director | filed 2010 - 2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.